How To Pay For The New Wave Of Gene Therapies
New models of paying for gene therapies will emerge as more of these innovative treatments, particularly outside the rare disease and oncology spaces, hit the market.
You may also be interested in...
NICE’s rapid decision to recommend funding in England and Wales for Novartis’s gene therapy Luxturna is a result of what the company calls its "collaborative and transparent" approach to negotiations over the health technology assessment of innovative new therapies. Novartis explains why this appraisal process was completed so quickly.
The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.
The number of conditional marketing authorization non-renewals could increase.